DA Davidson Has Negative Outlook for USNA Q1 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at DA Davidson reduced their Q1 2025 earnings per share estimates for USANA Health Sciences in a report released on Thursday, February 27th. DA Davidson analyst C. Xue now anticipates that the company will post earnings of $0.76 per share for the quarter, down from their prior estimate of $0.83. DA Davidson has a “Neutral” rating and a $36.00 price objective on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. DA Davidson also issued estimates for USANA Health Sciences’ Q1 2025 earnings at $0.76 EPS, FY2025 earnings at $2.38 EPS, FY2025 earnings at $2.38 EPS and FY2026 earnings at $2.59 EPS.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million.

USNA has been the topic of several other research reports. Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th.

USANA Health Sciences Stock Up 3.2 %

Shares of USANA Health Sciences stock opened at $29.55 on Friday. USANA Health Sciences has a 52 week low of $27.71 and a 52 week high of $50.32. The business’s fifty day simple moving average is $33.50 and its 200-day simple moving average is $36.56. The firm has a market cap of $563.22 million, a PE ratio of 10.44, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87.

Institutional Investors Weigh In On USANA Health Sciences

Several institutional investors and hedge funds have recently modified their holdings of the company. Public Employees Retirement System of Ohio raised its holdings in shares of USANA Health Sciences by 635.5% in the 4th quarter. Public Employees Retirement System of Ohio now owns 5,075 shares of the company’s stock valued at $182,000 after buying an additional 4,385 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of USANA Health Sciences by 83.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,300 shares of the company’s stock valued at $621,000 after buying an additional 7,877 shares during the period. Millennium Management LLC purchased a new stake in shares of USANA Health Sciences in the 4th quarter valued at $633,000. Lazard Asset Management LLC raised its holdings in shares of USANA Health Sciences by 24,765.5% in the 4th quarter. Lazard Asset Management LLC now owns 7,211 shares of the company’s stock valued at $258,000 after buying an additional 7,182 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its holdings in shares of USANA Health Sciences by 16.7% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 128,976 shares of the company’s stock valued at $4,629,000 after buying an additional 18,490 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.